title: p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer.
abstract: Tumor suppressor genes such as p53 contribute to the oncogenic process via loss-of-function mechanisms such as genetic mutation or complex formation with other cellular or viral proteins. p53 is mutated in approximately 50% of human tumors and has an important role in the genesis or progression of both colorectal and hepatocellular cancers. Colorectal cancer is leading cause of cancer mortality in the United States, whereas hepatocellular cancer is the leading worldwide cause of cancer death; the liver is a primary site of morbidity in both diseases. Because systemic tumor suppressor gene therapy is currently not feasible, we have chosen to develop a regional form of such therapy directed at primary or metastatic liver neoplasms. Gene replacement therapy with p53 is a promising new strategy to treat advanced human cancers.
authors.affiliation: Canji, Inc, San Diego, California 92121, USA.
authors.forename: R
authors.initials: R
authors.lastname: Bookstein
authors.forename: W
authors.initials: W
authors.lastname: Demers
authors.forename: R
authors.initials: R
authors.lastname: Gregory
authors.forename: D
authors.initials: D
authors.lastname: Maneval
authors.forename: J
authors.initials: J
authors.lastname: Park
authors.forename: K
authors.initials: K
authors.lastname: Wills
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics; D014407:Tumor Cells, Cultured